The emergence of Retatrutide ZPHC, at a strength of 120mg, is generating considerable buzz within the weight loss community. This novel dual GIP and GLP-1 receptor medication seems to offer notable improvements in body reduction compared to current therapies. Early clinical data have indicated marked reductions in body mass , conceivably marking a